Measurable residual disease (MRD) monitoring by next-generation sequencing before allogeneic hematopoietic cell transplantation in AML

Molecular measurable residual disease (MRD) assessment is not established in approximately 60 percent of acute myeloid leukemia (AML) patients due to the lack of suitable markers for quantitative real-time PCR. To overcome this limitation we established an error-corrected next-generation-sequencing...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Thol, Felicitas, Gabdoulline, Razif, Liebich, Alessandro, Klement, Piroska, Schiller, Johannes, Kandziora, Christian, Hambach, Lothar, Stadler, Michael, Koenecke, Christian, Flintrop, Madita, Pankratz, Mira, Wichmann, Martin, Neziri, Blerina, Büttner, Konstantin, Heida, Bennet, Klesse, Sabrina, Chaturvedi, Anuhar, Kloos, Arnold, Göhring, Gudrun, Schlegelberger, Brigitte, Gaidzik, Verena I., Bullinger, Lars, Fiedler, Walter, Heim, Albert, Hamwi, Iyas, Eder, Matthias, Krauter, Jürgen, Schlenk, Richard F., Paschka, Peter, Döhner, Konstanze, Döhner, Hartmut, Ganser, Arnold, Heuser, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116653/
https://ncbi.nlm.nih.gov/pubmed/30190321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-02-829911
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia